SANION.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:23):

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark...

Stats
今日成交量	386 306
平均成交量	395 716
市值	206.68M
EPS	SEK0 ( 2024-02-28 )
下一个收益日期	( SEK0 ) 2024-05-29
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.290
ATR14	SEK0.0130 (0.70%)

音量相关性

長: 0.16 (neutral)

短: -0.25 (neutral)

Signal:(60.281) Neutral

Saniona AB (publ) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Saniona AB (publ) 相关性 - 货币/商品

-0.04
( neutral )

-0.47
( neutral )

0.00
( neutral )

-0.59
( weak negative )

0.00
( neutral )

0.42
( neutral )

Saniona AB (publ) 财务报表

Annual	2023
营收:	SEK16.84M
毛利润:	SEK-79.35M (-471.18 %)
EPS:	SEK-1.290

FY	2023
营收:	SEK16.84M
毛利润:	SEK-79.35M (-471.18 %)
EPS:	SEK-1.290

FY	2022
营收:	SEK15.28M
毛利润:	SEK10.81M (70.72 %)
EPS:	SEK-3.33

FY	2021
营收:	SEK10.48M
毛利润:	SEK5.85M (55.81 %)
EPS:	SEK-6.59

Financial Reports:

No articles found.

Saniona AB (publ)

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.